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ity of the receptor or serve as recruitment sites for
downstream signaling proteins (reviewed by Pawson,
1995). Activated FGFRs transmit their signal by recruit-Summary
ing signaling molecules to the tyrosine autophosphory-
lation site in the carboxy-terminal tail of the receptorThe crystal structure of FGF2 bound to a naturally
(Mohammadi et al., 1992; Peters et al., 1992). In addition,occurring variant of FGF receptor 1 (FGFR1) consisting
FGFRs tyrosine phosphorylate a family of docking pro-of immunoglobulin-like domains 2 (D2) and 3 (D3) has
teins that recruit additional signaling proteins crucial forbeen determined at 2.8 AÊ resolution. Two FGF2:FGFR1
signal transmission (Kouhara et al., 1997).complexes form a 2-fold symmetric dimer. Within each
FGF±FGFR binding specificity is an essential elementcomplex, FGF2 interacts extensively with D2 and D3
in regulation of FGF activity. Each of the four membersas well as with the linker between the two domains.
of the FGFR family binds to a unique subset of FGFsThe dimer is stabilized by interactions between FGF2
(Ornitz et al., 1996). The overall complexity of the FGF±and D2 of the adjoining complex and by a direct inter-
FGFR system is further increased through alternativeaction between D2 of each receptor. A positively
splicing of FGFR mRNA (reviewed by Jaye et al., 1992;charged canyon formed by a cluster of exposed basic
Johnson and Williams, 1993). Natural FGFR isoformsresidues likely represents the heparin-binding site. A
lacking D1 or both D1 and the acid box, a continuousgeneral model for FGF- and heparin-induced FGFR
stretch of acidic residues in the linker between D1 anddimerization is inferred from the crystal structure, uni-
D2, have been isolated for FGFR1 and FGFR2 and havefying a wealth of biochemical data.
been shown to retain the full capacity to bind different
FGFs (reviewed by Johnson and Williams, 1993). Thus,
D2 and D3 are sufficient for FGF binding and for confer-Introduction
ring specificity.
An important splicing event occurs in D3 and has beenThe mammalian fibroblast growth factor (FGF) family
shown to be important in determining ligand bindingconsists of at least 18 structurally related polypeptides
specificity. The genomic sequence of this region in(FGF1±18) that are expressed in a specific spatial and
FGFR1±3 contains two exons (IIIb and IIIc) for the sec-temporal manner in embryo and adult vertebrates. FGFs
ond half of D3 (Johnson et al., 1991; Miki et al., 1991;play key roles in a wide variety of crucial biological
Avivi et al., 1993). The critical role of the second half ofactivities that require cell growth, differentiation, migra-
D3 in conferring ligand specificity is best exemplified bytion, and chemotaxis (reviewed by Burgess and Maciag,
the FGFR2/KGFR (keratinocyte growth factor receptor)1989; Galzie et al., 1997; Naski and Ornitz, 1998). Two
system. Both FGFR2 and KGFR are encoded by theclasses of cell surface receptors have been identified
same gene. In FGFR2, the second half of D3 is encoded
for FGFs: high-affinity and low-affinity receptors. The
by exon IIIc, while in KGFR it is encoded by exon IIIb.
four high-affinity receptors, FGFR1±FGFR4, are com-
Both FGF1 and FGF7 (KGF) bind to KGFR with high
posed of an extracellular ligand-binding domain that affinity, while FGF2 binds poorly to KGFR. In contrast,
contains three immunoglobulin (Ig)-like domains (D1± both FGF1 and FGF2 bind with high affinity to FGFR2,
D3), a single transmembrane helix, and a cytoplasmic whereas FGF7 does not bind to FGFR2 (Dell and Wil-
domain that contains protein tyrosine kinase activity liams, 1992; Miki et al., 1992; Yayon et al., 1992).
(reviewed by Jaye et al., 1992; Johnson and Williams, To elucidate the molecular mechanisms underlying
1993). The low-affinity FGF receptors are heparin and FGF±FGFR activation and specificity, we have deter-
heparan sulfate±containing proteoglycans (HSPGs) (re- mined the crystal structure of the extracellular ligand-
viewed by Burgess and Maciag, 1989). binding domain of FGFR1 (D2±D3) in complex with FGF2
Ligand-induced dimerization is a key event in trans- at 2.8 AÊ resolution. Although no heparin analog was
membrane signaling by receptors with tyrosine kinase included in the crystallization conditions, the FGF2±
activity (reviewed by Lemmon and Schlessinger, 1994). FGFR1 complex forms a noncrystallographic 2-fold di-
Unlike other growth factors (e.g., platelet-derived growth mer. This dimeric structure reveals the mechanism by
factor [PDGF]), which are dimeric, FGFs are monomeric which FGF and heparin cooperate to promote FGFR
and are unable by themselves to induce FGFR activa- dimerization and activation.
tion. FGFs function in concert with either soluble or cell
surface±bound HSPGs to promote FGFR dimerization, Results and Discussion
activation, and induction of biological responses (Ornitz
Structure Determination
A construct encoding Ig-like domains 2 (D2) and 3 (D3)³ To whom correspondence should be addressed (e-mail: mohammad
@saturn.med.nyu.edu). of the extracellular domain of FGFR1, residues 142 to
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Table 1. Summary of Crystallographic Analysis
Data Collection Statistics
Resolution (AÊ ) Reflections (Total/Unique) Completeness (%) Rsyma (%) Signal (kl/sll)
25.0±2.8 196,126/24,726 99.8 (98.1)b 7.2 (25.5)b 18.3
Refinement Statisticsc
Root-Mean-Square Deviations
Resolution (AÊ ) Reflections Rcryst/Rfreed (%) Bonds (AÊ ) Angles (8) B Factorse (AÊ 2)
25.0±2.8 23,830 24.0/28.4 0.008 1.4 1.7
aRsym 5 100 3 ShklSi |li(hkl) 2 kl(hkl)l|/ShklSi li(hkl).
bValue in parentheses is for the highest resolution shell: 2.9±2.8 AÊ .
cAtomic model: 5,173 protein atoms and 4 SO4 ions.
dRcryst/free 5 100 3 Shkl ||Fo(hkl)| 2 |Fc(hkl)||/Shkl lFo(hkl)|, where Fo (.2s) and Fc are the observed and calculated structure factors, respectively.
Five percent of the reflections were used for calculation of Rfree.
eFor bonded protein atoms.
365, was expressed in Escherichia coli. This construct Williams and Barclay, 1988), as previously predicted on
the basis of sequence alignments (Bateman and Chothia,(D23) is missing Ig-like domain 1 (D1), the acid box, and
the linker between D3 and the transmembrane helix. 1995). The fold of D2 can be described as a b barrel
formed by two layers of b sheets. One sheet is formedThe boundaries of this construct were chosen based on
limited proteolysis experiments, which were performed by strands bA, bB/bB9, bE, and bD, and the other by
strands bA9, bG, bF, bC, and bC9 (Figure 2A). A disulfideon the entire extracellular domain of FGFR1, expressed
in insect cells, in complex with FGF1. D23 is very similar bond between Cys-178, located between bB and bB9,
and Cys-230, situated on bF, bridges the two b sheets.to a naturally occurring splice variant of FGFR1 that
retains full ligand binding capacity (Johnson et al., 1990). This disulfide bond is buried in the hydrophobic core of
the domain. The overall strand topology of D2 is similarWhen expressed in E. coli, D23 was found entirely in
inclusion bodies and was solubilized using denaturating to that of the canonical I-set member telokin (Holden et
al., 1992). Indeed, D2 and telokin can be superimposedreagents and refolded in vitro. Following purification by
ion exchange chromatography, D23 was complexed (78 common Ca atoms) with a root-mean-square (rms)
deviation of only 0.8 AÊ . Nevertheless, there are signifi-with FGF2 and purified by size exclusion chromatogra-
phy. The elution position was consistent with the forma- cant deviations between D2 and telokin. Strands bA and
bE in D2 are shorter than the corresponding strands intion of a 1:1 FGF2±D23 complex. Tetragonal crystals
of FGF2±D23 were obtained using ammonium sulfate telokin. As a result, bB in D2 is discontinuous, consisting
of two short strands, bB and bB9. Another differenceas a precipitating agent. The crystals contain two 1:1
FGF2:D23 complexes in the asymmetric unit, related by occurs in the crossover connection between strands bA
and bA9. In D2, there is a four-residue insertion vis-aÁ -an approximate 2-fold axis.
The crystal structure of FGF2±D23 was solved by mo- vis telokin, which forms a 310 helix (helix A) that bulges
out from the main body of the domain.lecular replacement using FGF2 and telokin as search
models (see Experimental Procedures for details). The Superposition of D3 with telokin (71 common Ca
atoms) also gives an rms deviation of only 0.8 AÊ . A majorstructure has been refined at 2.8 AÊ resolution with an R
value of 24% (free R value of 28%). The atomic model difference in topology between D3 and telokin, and also
between D3 and D2, occurs after bC. In D3, a largeconsists of two FGF2 molecules (residues 16±144), two
D23 molecules (residues 149±359), and four sulfate ions. insertion of 14 residues forms an extended loop between
bC and bC9 (Figure 2A). This loop is ordered in only oneData collection and refinement statistics are given in
Table 1. of the two D23 molecules in the asymmetric unit. bC9
is substantially longer in D3 and directs the polypeptide
chain toward the upper end of the domain. bD is missingDescription of the Structure
The dimer in the asymmetric unit of the crystal com- altogether in D3, and in its place is a short a helix (aD).
Significantly, this divergent portion of D3 contacts theprises two 1:1 FGF2±D23 complexes (Figure 1). Within
each complex, FGF2 interacts extensively with D2, D3, ligand (see below). The D3 chain reconverges with D2
and telokin at bE. The disulfide bond in the hydrophobicand the linker between the two domains. The dimeric
structure is stabilized by direct receptor±receptor inter- core of D3 is made between Cys-277 and Cys-341.
actions (D2±D2) and interactions between FGF2 and D2
of the other receptor in the dimer. The two FGF2 ligands
are on opposite sides of the dimer and are not in contact. Primary Interaction Site between FGF2 and FGFR1
FGF2 interacts with residues in D2 and D3 as well as inAs reported previously (Eriksson et al., 1991; Zhang et
al., 1991; Zhu et al., 1991), FGF2 adopts a b-trefoil fold the linker between D2 and D3 (Figures 3 and 4). These
interactions constitute the primary FGF2±FGFR1 inter-that consists of three copies of a four-stranded antipar-
allel b sheet. action site. The interface between the ligand and recep-
tor is extensive, with a total of z2700 AÊ 2 of accessibleThe three-dimensional folds of D2 and D3 place them
in the I-set subgroup of the Ig superfamily (reviewed by surface area buried. The primary interaction site will be
Crystal Structure of FGF2±FGFR1
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Figure 1. Ribbon Diagram of the Dimeric
FGF2±D23 Structure, in Two Views Related
by a Rotation of Approximately 908 about the
Vertical Axis
The Ig-like domains 2 (D2) and 3 (D3) of the
two D23 molecules are shown in green and
blue, respectively. The short linker that con-
nects D2 and D3 is colored gray. The two FGF2
molecules are shown in orange. The loop be-
tween bC and bC9 is ordered in only one of the
two D23 molecules. This loop has been grafted
onto the second D23 molecules and indicated
as a dotted line. This figure was created using
the programs Molscript and Raster3D (Kraulis,
1991; Merrit and Bacon, 1997).
described first with respect to D2, then to the D2±D3 crystal structure, the side chains of His-166 and Val-168
are partially buried in the hydrophobic core of D2 andlinker, and finally to D3.
are clearly important for proper folding of D2. In contrast,Apart from a single hydrogen bond between the side
in the crystal structure of cadherin (Shapiro et al., 1995),chain of Tyr-24 in FGF2 and the backbone of Leu-165 in
the side chains of the HAV motif are all solvent exposedFGFR1, hydrophobic interactions dominate the interface
and poised for homophilic interaction.between FGF2 and D2 (Figure 5A). The side chains of
The linker between D2 and D3 is highly conservedTyr-24 and Met-142 of FGF2 are in hydrophobic contact
among the four members of the FGFR family (Figurewith Ala-167 of D2, and the side chains of Asn-102, Tyr-
2B). Arg-250 in the linker is invariant and is seen in the103, and Leu-140 of FGF2 form a hydrophobic patch
crystal structure to be directly involved in ligand bindingwith Pro-169 of D2. Ala-167 and Pro-169 are located in
and in interaction with D3. The guanidinium group ofbA9 of D2. The aliphatic side chain of Val-248, located
Arg-250 makes two hydrogen bonds with FGF2: onein the linker region of FGFR1, interacts with Leu-140 of
with the backbone carbonyl oxygen of Asn-102 and an-FGF2 and contributes to the hydrophobicity of FGF2±D2
other with the side chain carbonyl oxygen of Asn-104interface (Figure 5A). Ala-167, Pro-169, and Val-248 of
(Figure 5B). The side chain amide group of Asn-104 inD2 are well conserved among the four mammalian
FGF2 is also engaged in an intramolecular hydrogenFGFRs (Figure 2B), suggesting that this hydrophobic
bond with Tyr-106 of FGF2, which in turn is hydrogensurface may represent a conserved interaction site for
bonded to Glu-96, an invariant residue in the FGF family.other FGF family members.
The side chain of Glu-96 is hydrogen bonded to theThe hydrophobic interactions observed in the crystal
backbone amide nitrogen of Gln-284 in D3 (Figure 5B).structure between FGF2 and D2 are in agreement with
The intramolecular FGF hydrogen bonds most likelybiochemical studies by Springer et al. (1994), who have
serve to restrict the conformational freedom of the Asn-mutated solvent-exposed residues of FGF2 based on
104 and Glu-96 side chains, minimizing the entropic costthe unliganded FGF2 crystal structure (Eriksson et al.,
of receptor binding.1991; Zhang et al., 1991; Zhu et al., 1991) and tested
Site-directed mutagenesis studies confirm the impor-these mutants for FGFR1 binding and mitogenic activity.
tance of these FGF residues in receptor binding. Re-
The binding site, as mapped by Springer et al. (1994),
placement of Asn-104 by alanine resulted in a .400-
consists primarily of the hydrophobic residues Tyr-24,
fold loss of receptor binding affinity (Zhu et al., 1997),
Tyr-103, Leu-140, and Met-142 of FGF2. Individual sub- while replacement of Glu-96 with alanine resulted in a
stitutions of these hydrophobic residues in FGF2 with 1000-fold reduction (Zhu et al., 1995). Substitution of
alanine resulted in a dramatic decrease (.100-fold) in Tyr-106 with phenylalanine caused a 5-fold reduction in
FGFR1 binding. All four of these hydrophobic residues receptor binding (Zhu et al., 1995), indicating that Glu-
are found in the FGF2±FGFR1 interface in the present 96 and Asn-104 require intramolecular hydrogen bonds
structure. with the side chain of Tyr-106 for the proper positioning
Ala-167 of FGFR1, which interacts with FGF2, is part of of Glu-96 and Asn-104 for receptor interaction.
the conserved sequence motif 166HAV168 found in FGFRs. The side chains of Val-248 in the D2±D3 linker and
This motif is a hallmark of cell adhesion molecules Leu-98 in FGF2 create a hydrophobic environment for
(CAMs) and has been shown to be important for homo- the aliphatic portion of the Arg-250 side chain. Two
philic interactions between CAMs on different cells intramolecular hydrogen bonds between the Arg-250
(Blaschuk et al., 1990; Noe et al., 1999). It has been guanidinium group and the side chain carboxylate group
proposed that neurite outgrowth stimulated by a subset of Asp-282 in D3 (Figure 5B) probably serve to restrict
of CAMs is mediated by FGFR activation (Doherty et al., the rotational freedom of the Arg-250 side chain so that
1995). According to this model, CAMs activate FGFRs it is poised (small entropic loss) to interact with the
by interacting directly with FGFRs via the HAV motif ligand. Reciprocally, this interaction may also help to
orient D3 for optimal interaction with the ligand.(reviewed by Doherty and Walsh, 1996). However, in the
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Figure 2. Overall Topology of the Ig-like Do-
mains D2 and D3 of FGFR1 and Sequence
Alignment of the Ligand-Binding Domain in
the FGFR Family
(A) Comparison of the overall folds of D2 and
D3 of FGFR1 with that of the I-set member
telokin. The b strands are labeled according
to the telokin fold, from A to G. The helix
between bA and bA9, gA, is a 310 helix. The
cysteines forming the disulfide bridge be-
tween the two b sheet layers in D2 and D3
are rendered in ball-and-stick. The amino and
carboxyl termini are denoted by NT and CT.
This figure was created using the program
Molscript.
(B) Structure-based sequence alignment of
the ligand-binding domain (D2, D2±D3 linker,
and D3) of the four human FGF receptors
(FGFR1±4). The secondary structure assign-
ments for FGFR1 were obtained using the
Kabsch and Sander algorithm as imple-
mented in PROCHECK (Laskowski et al.,
1993). The location and length of the strands
and helices are shown on the top of the se-
quence alignment. The letter ªgº denotes a
residue in a 310 helix. Only 310 helices compris-
ing four or more residues are indicated. D2
and D3 are demarcated by green and blue
boxes, respectively. A period represents se-
quence identity to FGFR1. FGFR residues in-
volved in direct receptor±receptor interaction
are shown in yellow. FGFR residues engaged
in the primary FGF2±FGFR1 interaction site
are colored red. In blue are FGFR residues
that form the sides of the positively charged
canyon between the D2 domains in the dimer.
FGFR residues participating in the secondary
FGF±FGFR interaction site are colored pur-
ple. Residues that are engaged in two interac-
tion sites are bicolored.
The interactions between D3 and FGF2 take place at His-16, it is conceivable that there are additional interac-
tions with D3 involving FGF2 residues N-terminal to Gly-the upper end of D3 (Figures 3 and 4). Many of these
interactions involve residues in the segment between 15, the most divergent region in FGFs. The involvement
of Phe-17 in receptor binding is supported by inhibitionbC9 and bE, which is structurally divergent from D2 and
other members of the I-set family (Figure 2A). Several of FGF2 binding to FGFR1 and by inhibition of FGF2-
induced proliferation of vascular endothelial cells usingregions of FGF2 interact with D3, including the N-termi-
nal segment of FGF2, outside of the b-trefoil core (Figure a hexapeptide corresponding to FGF2 residues 13±18
that was identified by phage display experiments (Yayon5C). The side chain of Phe-17 in FGF2 inserts into a
shallow hydrophobic pocket in D3 formed by Pro-285, et al., 1993).
Residues 56±60 of FGF2, in b4 and the b4±b5 loop,Ile-287, and the aliphatic portions of the Glu-324 and
Asp-320 side chains (Figure 5C). In addition, the back- are in close vicinity to D3 and contribute to ligand bind-
ing (see Figure 3). The side chain of Gln-56 makes twobone of Phe-17 is hydrogen bonded to the Gln-284 side
chain. The side chain of Lys-21, another residue in the hydrogen bonds with Asp-320 in aD of D3, one with
the backbone amide nitrogen and another with the sideN-terminal segment of FGF2, forms a hydrogen bond
with the side chain of Gln-284 and the backbone of Asp- chain carboxylate group (Figure 5C). In addition, the
aliphatic portion of the Gln-56 side chain is in van der282 (Figure 5C).
The N-terminal boundary of FGF2, Gly-15, was chosen Waals contact with Gly-315. Ala-57 makes van der Waals
contacts with Pro-285 and Gly-315. Glu-58 is hydrogenbased on the crystal structure of FGF2 (Faham et al.,
1996), in which the first ordered residue is Pro-20. Given bonded via its side chain carboxylate group to the back-
bone amide nitrogen of Val-316 and is also within van derthat the first ordered residue in the present structure is
Crystal Structure of FGF2±FGFR1
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demonstrating that FGF1, FGF2, FGF4, and FGF9 are
not capable of binding to either D2 or D3 alone (M. M.
et al., unpublished results). It is interesting to note that
while the interactions between FGF2 and D3 are of both
hydrophobic and polar character, hydrophobic contacts
dominate the interface between FGF2 and D2.
Ligand±Receptor Interactions
that Stabilize Dimerization
The dimer observed in the crystal structure is stabilized
by a direct receptor±receptor interaction and by con-
tacts between FGF2 and the other receptor in the dimer,
which we designate as the secondary interaction site.
These interactions, which are relatively few compared
to those in the primary FGF±FGFR interaction site, may
aid in FGF- and heparin-induced FGFR dimerization but
are presumably not of sufficient strength to allow hepa-
rin-independent FGF-induced FGFR dimerization in the
context of the native receptor.
The total accessible surface area buried in the sec-
ondary interaction site is only 735 AÊ 2 (Figure 4). Apart
from a backbone±backbone hydrogen bond between
Pro-132 of FGF2 and Gly-204 of the receptor (in D2),
the remainder of the interactions are van der Waals
contacts. Residues of FGF2 in the b8±b9 loop (Asp-99,
Ser-100, Asn-101) and the b11±b12 loop (Pro-132, Gly-
133, Leu-138) are in van der Waals contact with D2
residues in the bC9±bD loop (Pro-199, Asp-200, Ile-203,
Gly-204, Gly-205) and the bE±bF loop (Ser-219, Val-221).
The side chain of Lys-26 in FGF2 forms a hydrogen bond
with the side chain of Asp-218 of D2. Because Lys-26Figure 3. Mapping of the Different Interaction Sites onto the Ribbon
Representations of FGF2 and FGFR1 has been identified as a heparin-binding residue (Faham
The color codings for D2, D3, the linker, and FGF2 are the same as et al., 1996), the observed interaction with Asp-218 may
in Figure 1. The amino and carboxyl termini are denoted by NT and or may not occur in the presence of heparin. Interest-
CT. The b strands of FGF2 are labeled from 1 to 12 according to ingly, a secondary FGFR1-binding site on FGF2 was
published nomenclature (Faham et al., 1996). Residues of FGF2 and
identified previously, consisting of Lys-110, Tyr-111, andD23 engaged in the primary interaction site are shown in red. FGF2
Trp-114 (Springer et al., 1994). However, these residuesand D23 residues engaged in the secondary interaction site are
are not found in the secondary interaction site in thecolored purple. FGFR1 residues involved in direct receptor±receptor
interaction are shown in yellow. Residues of FGF2 known to bind dimer and, in fact, are quite distant from the receptor.
to heparin are shown in blue. Also in blue are FGFR1 residues Superposition of receptor-bound FGF2 with free FGF2
proposed (based on the present structure) to interact with heparin. (Zhang et al., 1991) shows that the only significant struc-
In this figure, FGF2 has been pulled away from FGFR1. This figure
tural change that occurs upon receptor binding is in thewas created using the programs Molscript and Raster3D.
secondary interaction site of FGF2. The b turn containing
Ser-100, Asn-101, and Asn-102 undergoes a conforma-
tional shift to optimize the interaction with the receptor.Waals distance of His-286 and Gly-315. The backbone of
Glu-59 is in van der Waals contact with the side chain Since Asn-101 is a residue in the secondary interaction
site and not the primary site, mutation of this residueof His-286. The guanidinium group of Arg-60 is hydrogen
bonded to the backbone carbonyl oxygen of Asn-345. should not affect formation of the 1:1 FGF2:FGFR1 com-
plex. This is in accord with Zhu et al. (1997) but is con-This region of FGF2 (residues 56±60) is divergent among
the 18 FGF family members, suggesting that these resi- trary to the study by Springer et al. (1994), who reported
that replacement of Asn-101 with alanine results in adues may confer FGF±FGFR specificity.
In the absence of ligand, Val-316 of D3, in the bC9±aD 7-fold decrease in FGF2 binding to FGFR1. In the crystal
structure of FGF2 complexed with a hexasaccharideloop, would be solvent exposed. However, in the com-
plex, Val-316 is engaged in a hydrophobic interaction (Faham et al., 1996), Asn-101 is hydrogen bonded to
one of the hexasaccharide sulfate groups and consti-with Val-88 of FGF2. Mutagenesis experiments support
the involvement of Val-88 in receptor binding. Replace- tutes part of the low-affinity heparin-binding site. The
present structure shows that receptor engagementment of Val-88 with alanine in FGF2 causes a 10-fold
reduction in receptor binding affinity (Zhu et al., 1998). would preclude Asn-101 from contributing to heparin
binding.The present structure shows why ligand binding and
specificity require both D2 and D3 of FGFRs and contra- In general, the ligand±receptor contacts in the sec-
ondary interaction site are nonspecific in nature, for ex-dicts reports that suggest D2 of FGFR1 by itself can
bind FGFs (Cheon et al., 1994; Wang et al., 1999). This ample, backbone±backbone van der Waals contacts.
Such interactions would allow other ligand±receptorconclusion is also consistent with our in vitro studies
Cell
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Figure 4. Mapping of the Different Interaction Sites onto the Molecular Surfaces of FGF2 and FGFR1
The surface color codings for D2, D3, the linker, and FGF2 are the same as in Figure 1. The surfaces of FGF2 and FGFR1 that form the primary
and secondary interaction sites are shown in red and purple, respectively. The heparin-binding surfaces are depicted in blue. The surface on
D2 engaged in direct receptor±receptor interaction is colored yellow. To better visualize the different functional surfaces on FGF2 and D23,
the two molecules are pulled away from each other and rotated 908 about the vertical axis. This figure was created using the program GRASP
(Nicholls et al., 1991).
combinations to adopt the same dimeric form as ob- The Proposed Heparin-Binding Canyon
Calculation of the electrostatic potential at the surfaceserved for FGF2±FGFR1.
of the dimer reveals a highly positive ªcanyonº whose
sides are the inward faces of D2 from the two receptorsReceptor±Receptor Interactions
that Stabilize Dimerization in the dimer (Figure 6B). The positive potential continues
onto the top side of the two ligands on either side of theThe dimeric structure is also stabilized by a direct recep-
tor±receptor interaction. The interaction between the canyon. The positive potential in the canyon is provided
primarily by the lysines that constitute the heparin-bind-two FGFR1 molecules in the dimer is limited to a region
of D2 at the bottom of the domain, involving residues ing site on D2 (Kan et al., 1993; Figure 6A). These lysines
are located in an 18-residue stretch from helix A throughin the bA9±bB and bE±bF loops (Figure 3). The total
surface area buried at this interface is only z300 AÊ 2 bB and include Lys-160, Lys-163, Lys-172, Lys-175, and
Lys-177. Although Lys-164 is contained in this region,(Figure 4). Across the 2-fold axis of the dimer, the Ala-
171 side chain makes a hydrophobic contact with the it is located on the outward face of D2. We propose that
this canyon is the site of heparin binding.Ala-171 side chain from the other receptor. Main chain
atoms of Ala-171 and Lys-172 are in van der Waals While the side chains of Lys-160, Lys-175, and Lys-
177 are disordered (probably due to the lack of heparin),contact with the corresponding atoms in the adjacent
receptor. Hydrogen bonds between the side chain of the side chains of Lys-163 and Lys-172 are ordered and
chelate a sulfate ion located in the canyon at the junctionThr-173 and the backbone nitrogen of Thr-173 of the
other receptor and between the side chains of Lys-172 between the ligand and receptor. The same sulfate ion
is also chelated by Lys-26 and Lys-135 from the ligand.and Asp-218 fortify the interface.
Sequence conservation in this region of D2 among Based on the crystal structure of FGF2 complexed with
a hexasaccharide (Faham et al., 1996), these two lysinesFGFRs is consistent with this region forming a receptor±
receptor interface. The residue at the closest approach were assigned to the low-affinity heparin-binding site.
This observed sulfate-mediated ligand±receptor inter-in the dimer interface is Ala-171, which is conserved in
FGFR1±3 and replaced by glycine in FGFR4 (Figure 2B). action may explain in part why heparin increases the
apparent affinity of FGF2 for FGFR1 (Roghani et al.,In addition, the hydrogen-bonding potential at the inter-
face is conserved in FGFR2-4. Asp-218 and Lys-172 1994).
The high-affinity heparin-binding site on FGF2 con-in FGFR1 are replaced by potential hydrogen-bonding
partners glutamic acid and asparagine, respectively, in sists of Asn-27, Lys-125, Gln-134, and Arg-120 (Faham
et al., 1996). These residues are located on the top sur-FGFR2-4. Thr-173 is conserved in all four FGFRs (Figure
2B). Intriguingly, the interactions observed at the recep- face of FGF2 adjacent to the end of the canyon. An
ordered sulfate ion is bound in the high-affinity heparin-tor±receptor interface are compatible with FGFR hetero-
dimerization, which has been detected in transfected binding site of each of the two FGF2 molecules in the
dimer (Figure 6A). In addition to the modeled sulfatecell lines expressing FGFR1 and FGFR2 (Bellot et al.,
1991). A role for direct receptor±receptor interaction in ions, there are several positive peaks in the difference
electron density map within the canyon that are likelyFGFR dimerization has been postulated previously (Pan-
toliano et al., 1994; Wang et al., 1997). However, the ob- to represent partially ordered sulfate ions. In the ab-
sence of heparin, the sulfate ions are probably importantserved receptor±receptor interface in the crystal struc-
ture differs from those previously proposed. for neutralizing the many positively charged residues
Crystal Structure of FGF2±FGFR1
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Figure 5. The Primary Interaction Site be-
tween FGF2 and FGFR1
(A) Stereo view of the hydrophobic interface
between FGF2 and D2 of FGFR1. Only side
chains of interacting residues are shown.
Color coding is the same as in Figure 1: FGF2
in orange, D2 in green, D3 in blue, and the
linker in gray. Dotted lines represent hydro-
gen bonds.
(B) Stereo view of the network of hydrogen
bonds between FGF2 and FGFR1 in the vicin-
ity of Arg-250 in the D2±D3 linker.
(C) Stereo view of the interface between FGF2
and D3 of FGFR1. This figure was created
using the programs Molscript and Raster3D.
of D2 in the canyon, allowing formation of the dimer. dodecasaccharide could engage residues in both the
low- and high-affinity sites on the two ligands (Figure 6B).Moreover, the sulfate ions most likely demarcate the
path of a bound heparin molecule, which would traverse The crystal structure suggests that other basic resi-
dues of D2 that point into the canyon may also be in-the canyon and interact with the heparin-binding sites
on the receptors and the ligands at the ends of the volved in heparin binding, although they have not been
implicated previously. Lys-207 and Arg-209 are situatedcanyon.
The hypothesis that the canyon represents the site at the top of the canyon in bD. Lys-207 is conserved in
FGFR1±3, and an arginine is present at this position inof heparin binding is further supported by biochemical
studies aimed at determining the minimal length of hepa- FGFR4. Arg-209 is conserved in all four FGFRs (Figure
2B). Interestingly, Ala-211, which is nearby and alsorin necessary for FGF signaling (Ornitz et al., 1992). The
results indicate that the shortest biologically active hep- points into the canyon, is a glutamine in FGFR2-4, a
residue that can form a hydrogen bond with the sulfatearin oligosaccharide is an octasaccharide and that an
increase in activity parallels an increase in heparin length groups of heparin. It is likely that sequence differences
in the heparin-binding region in FGFRs modulate theup to a dodecasaccharide, at which point the activity
plateaus. Manual docking of a hexasaccharide, which affinity and specificity for glycosaminoglycans, which
are naturally heterogeneous in carbohydrate sequenceis not biologically active, into the dimer canyon demon-
strates that while the hexasaccharide can interact with and sulfation.
the heparin-binding site on the receptor, it is not long
enough to reach the heparin-binding site on the ligands. Conclusions
The dimeric FGF:FGFR structure described in this reportIn contrast, an octasaccharide placed into the canyon
is able to reach the low-affinity heparin-binding site on reveals a detailed view of how a growth factor binds to
a naturally occurring variant of an extracellular domainthe two ligands. A longer oligosaccharide such as a
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of a receptor tyrosine kinase, leading to receptor dimer-
ization and activation. In addition, the salient features
of this structure enable the interpretation of a large body
of work describing the binding characteristics of FGF
and FGFR mutants, as well as how heparin in concert
with FGF induces FGFR dimerization and activation. We
conclude that multiple binding events contribute toward
the generation of a stable FGF:FGFR dimeric complex.
The present crystal structure reconciles the ability of
heparin to both induce dimerization of FGF and interact
with the heparin-binding region on FGFRs. A positively
charged canyon is formed between the two D2 domains
of FGFRs and extends onto the heparin-binding sites
on the ligands. We propose that this canyon represents
the heparin-binding site. In this model, FGF interacts
with both receptor molecules within the dimer through
primary and secondary sites. The direct receptor±
receptor interactions observed in our structure are con-
fined to a small interface located in D2 at the bottom of
the heparin-binding canyon. Both the direct receptor±
receptor interactions and the interaction of FGF2 with
the adjoining receptor contribute toward stabilization of
the dimeric structure. There are no direct interactions
between the two FGF molecules (Figure 6C).
The dimeric model deduced from the crystal structure
also affords a possible role for the acid box, a continuous
stretch of acidic residues in the linker between D1 and
D2. Modeling experiments show that the acid box has
the potential to interact with the basic heparin-binding
region on D2, especially since the linker between the
acid box and the beginning of D2 is long enough to
allow this interaction to occur. The model inferred from
the crystal structure implies that binding of heparin (in
the absence of FGF) to the heparin-binding surfaces
on D2 could cause FGF-independent dimerization of
FGFRs. Indeed, heparin-induced FGF-independent acti-
vation of FGFR4 has been described (Gao and Goldfarb,
1995). We surmise that in the context of the full-length
receptor, the acid box is bound to the basic heparin-
binding region on D2, thereby competing with heparin
for FGFR binding. This autoinhibition would prevent
FGF-independent activation of FGFR by heparin sulfate
proteoglycans that are found in abundance on the sur-
face of most cell types. Interaction of the acid box with
the heparin-binding region on D2 could also enable D1Figure 6. The Putative Heparin-Binding Canyon
to fold over onto D2 and D3 and affect the interaction(A) Molecular surface representation of the dimeric FGF2±FGFR1
with FGF. This hypothesis is consistent with studiescomplex. The view is from the top (with respect to the left panel in
Figure 1) looking down into the proposed heparin-binding canyon. demonstrating that an FGFR1 deletion mutant lacking
The surface coloring is the same as in Figure 4, with FGF2 in orange D1 and the acid box exhibits higher binding affinity for
and D2 in green. The side chains of the identified or proposed heparin- FGF and heparin (Wang et al., 1995). Interestingly, pro-
binding residues on D2 and the identified low- and high-affinity
gression of human pancreatic and brain tumors towardheparin-binding sites in FGF2 are rendered in ball-and-stick. The
malignancy has been correlated with a switch in alterna-ordered sulfate ions in the high-affinity heparin-binding site on FGF2
tive splicing of FGFRs leading to expression of FGFRsand in the canyon at the junction between FGF2 and D2 are shown.
(B) Surface charge distribution of the dimeric FGF2±FGFR1 complex. missing D1 and the acid box (Kobrin et al., 1993; Yama-
The view is the same as in (A). Blue and red represent positive and guchi et al., 1994).
negative electrostatic potential, respectively. Side chains of lysine,
arginine, glutamic acid, and aspartic acid that are disordered but
would point into the canyon were manually positioned. The posi- (C) Molecular surface view of the dimeric FGF2±FGFR1 complex with
tively charged canyon runs between the two D2 domains of the a heparin dodecasaccharide docked manually into the proposed
receptors in the dimer and extends across the adjoining ligands. heparin-binding site. Coloring and viewing angle are the same as
The positive potential of the surface is provided by the putative in Figure 1. The dodecasaccharide is sandwiched (trans) between
heparin-binding residues on D2 and the low- and high-affinity hepa- the D2 domains of the receptor monomers and interacts at both
rin-binding sites on FGF2. A heparin dodecasaccharide is docked ends with the FGF2 molecules in a cis manner. To see the path of
manually into the proposed heparin-binding site. This figure was the dodecasaccharide, the front D2 was made semitransparent. This
created with GRASP. figure was prepared with GRASP.
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